Production (Stage)
Perspective Therapeutics, Inc.
CATX
$2.39
-$0.12-4.78%
AMEX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 46.15% | -36.59% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 46.15% | -36.59% | |||
| Cost of Revenue | -65.93% | -- | |||
| Gross Profit | 66.39% | -10,658.54% | |||
| SG&A Expenses | -4.90% | 18.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.95% | 11.19% | |||
| Operating Income | -4.48% | -12.13% | |||
| Income Before Tax | 56.93% | -179.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 54.68% | -165.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 54.75% | -165.63% | |||
| EBIT | -4.48% | -12.13% | |||
| EBITDA | 47.75% | -124.76% | |||
| EPS Basic | 55.71% | -164.92% | |||
| Normalized Basic EPS | 2.12% | -19.88% | |||
| EPS Diluted | 77.93% | -431.62% | |||
| Normalized Diluted EPS | 2.12% | -19.88% | |||
| Average Basic Shares Outstanding | 2.17% | 0.27% | |||
| Average Diluted Shares Outstanding | 2.17% | 0.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||